The Mayo Clinic Cancer Center (MCCC) is a matrix center within the Mayo Clinic / Mayo Medical School. The Center is made up of 351 members from 87 departments and divisions based at 3 geographical sites (Rochester, MN - MGR; Jacksonville, FL - MCF; and Phoenix/ Scottsdale, AZ - MCA). Our mission is to promote and facilitate research on the incidence, etiology, and molecular basis of cancer, and then through education and direct application of the results of such research, translate the discoveries into improved methods for cancer prevention, detection, diagnosis, prognosis, and therapy. MCCC, like Mayo Clinic in general, serves not only patients in the immediate geographical areas of MGR, MCF, and MCA, but also patients from throughout the USA and the rest of the world. MCCC has 10 research programs: Cell Biology; Developmental Therapeutics; Cancer Immunology & Immunotherapy; Gene & Virus Therapy; Women's Cancer; Gastrointestinal Cancer; Hematologic Malignancies; Neuro-oncology; Genetic Epidemiology & Risk Assessment; and Cancer Prevention & Control. Research is facilitated by: 1) 13 shared resources: Survey Research, Pharmacy, Biostatistics, Bioinformatics, Biospecimens Accessioning & Processing, Pathology Research Core, Transgenic & Knockout Core, Proteomics, Microscopy & Cell Analysis, Pharmacology, Gene & Virus Therapy, Cytogenetics, and Gene Analysis; and 2) clinical support management activities including Clinical Trials Office, PRMS, and Data & Safety Monitoring. Since the last renewal, MCCC has grown with an increase in overall peer-reviewed funding from $105.9M to $123.6M and an increase in NCI funding from $75.7M to $92.7M. Of particular note is a new Ovarian SPORE and a new training grant. Furthermore, there has been successful competitive renewal of 4 other SPOREs (Lymphoma, Brain, Breast, Pancreas), as well as several multi-disciplinary and training grants. Research productivity and excellence is demonstrated by high-impact clinical and scientific publications - several of which have led to changes in cancer care. As the MCCC moves forward, a major cross-programmatic effort will be to build on research started during the past grant period in the cancer genome with the development of new genome-guided therapy approaches.

Public Health Relevance

The Mayo Clinic Cancer Center Support Grant provides the infrastructure support to facilitate basic, clinical, and population sciences research relevant to cancer research conducted within Mayo Clinic. The Center's goal is to translate the discoveries in the laboratory into improved methods for cancer prevention, detection, diagnosis, prognosis, and therapy. The ultimate goal is to relieve the burdens of illness in patients with canner.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015083-43S1
Application #
9378853
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Program Officer
Shafik, Hasnaa
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
43
Fiscal Year
2017
Total Cost
$60,000
Indirect Cost
$22,264
Name
Mayo Clinic, Rochester
Department
Type
Other Domestic Non-Profits
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066

Showing the most recent 10 out of 1129 publications